AVBP:NASDAQ, ArriVent BioPharma, Inc.

Why AVBP stock fell on November 16

ArriVent BioPharma, Inc. fell 11.1% on Monday, November 16, 2026, on 644,206 shares. No headline about AVBP came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

AVBP stock overview

ArriVent BioPharma, Inc. (AVBP:NASDAQ) closed at $11.26 on November 19, 2026, up 3.30% on the day. The stock trades 68.6% below its 52-week high of $35.83 and 9.0% above its 52-week low of $10.33. Over the past year, it lost 44.7%. ArriVent BioPharma, Inc. is part of the Health Care sector.

Key figures

Price
$11.26
Day change
+3.30%
Volume
906,598
Average volume
1,346,540
Market cap
582M+
52-week range
$10.33 – $35.83
50-day average
$20.20
200-day average
$26.31

Price action over the past year

In 252 trading sessions since November 19, 2025, AVBP closed higher on 122 days (48%). Its best day was May 29, 2026 (+12.24%) and its worst was October 6, 2026 (-46.98%). The stock moved 10% or more in a single session 13 times.

Recent signals

AVBP news

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.

Similar stocks

Find more stocks like AVBP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.